×
About 255 results

ALLMedicine™ Papillary Tumors Center

Research & Reviews  90 results

Immunohistochemical staining for IMP3 in patients with duodenal papilla tumors: assessm...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130282
BMC Gastroenterology; Tanaka H, Kawashima H et. al.

May 19th, 2021 - Endoscopic papillectomy of duodenal papillary tumors (PT) is indicated for adenomas or well-differentiated adenocarcinomas that do not involve the sphincter of Oddi. However, there is currently no reliable pre-operative method to diagnose the infi...

A clinicopathological reappraisal of intraductal papillary neoplasm of the bile duct (I...
https://doi.org/10.1016/j.hpb.2021.03.004
HPB : the Official Journal of the International Hepato Pa... Onoe S, Ebata T et. al.

Apr 9th, 2021 - Intraductal papillary neoplasm of the bile-duct (IPNB) has recently been further subclassified into "so-called IPNBs" (Type-1) and "narrow-sense papillary cholangiocarcinomas" (Type-2), but their differential diagnosis is challenging. This study a...

PTEN R130Q Papillary Tumor of the Pineal Region (PTPR) with Chromosome 10 Loss Successf...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025816
Current Oncology (Toronto, Ont.); Assi HI, Kakati RT et. al.

Apr 3rd, 2021 - Papillary tumors of the pineal region (PTPR) can be observed among adults with poor prognosis and high recurrence rates. Standards of therapy involve total surgical excision along with radiation therapy, with no promising prospects for primary adj...

Malignant Ciliated Muconodular Papillary Tumors of the Lung: A Case Report.
https://doi.org/10.1177/1066896920988359
International Journal of Surgical Pathology; Wang F, Shen MH et. al.

Feb 19th, 2021 - Ciliated muconodular papillary tumors (CMPTs) are rare peripheral lung lesions, characterized by papillary architecture and ciliated columnar cells admixed with mucous cells and basal cells. Only about 50 cases have been reported to date and is ca...

Papillary tumor of the pineal region in pediatric populations: An additional case and s...
https://doi.org/10.1016/j.clineuro.2020.106404
Clinical Neurology and Neurosurgery; Mathkour M, Hanna J et. al.

Dec 28th, 2020 - Papillary tumors of the pineal region (PTPR) are a rare tumor entity first described in 2003, later codified in the 2007 WHO tumor classification system. PTPRs most commonly occur in the third and fourth decades, with exceedingly rare presentation...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  3 results

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to...
https://clinicaltrials.gov/ct2/show/NCT03335059

Apr 14th, 2020 - This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate (CRR) and disease-free...

Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy
https://clinicaltrials.gov/ct2/show/NCT00233402

Oct 10th, 2013 - In superficial bladder cancer macroscopic tumors including non-invasive papillary tumors (Ta) in the bladder are relatively easy to visualize by cystoscopic examination under white light. However, dysplasia, carcinoma in situ (CIS) or small exophy...

Surgery and BCG in Treating Patients With Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT00002990

Jun 11th, 2013 - OBJECTIVES: Demonstrate that after complete transurethral resection of all papillary tumors, one third dose BCG (Bacillus Calmette-Guerin vaccine; OncoTICE) is equivalent to full dose BCG and short term maintenance is equivalent to long term maint...

see more →

News  8 results

Fast Five Quiz: Urothelial Carcinoma
https://reference.medscape.com/viewarticle/935309_2

Aug 12th, 2020 - Figure 1. Bladder cancer. Illustration of sagittal section of the female pelvis showing cancer in the muscular wall of the bladder. Additional anatomy shown includes the uterus, vagina, and portions of the rectum and small intestine. Low-grade pro...

FDA approves pembrolizumab for BCG-unresponsive NMIBC with CIS
https://www.mdedge.com/hematology-oncology/article/215228/genitourinary-cancer/fda-approves-pembrolizumab-bcg-unresponsive?channel=39313
Laura Nikolaides

Jan 8th, 2020 - The Food and Drug Administration has approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or with.

FDA Approves Pembrolizumab for High-Risk Bladder Cancer
https://www.staging.medscape.com/viewarticle/923568

Jan 7th, 2020 - UPDATED with comments January 9, 2020 // The US Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda, Merck) for the treatment of patients with bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle invasive bladder ...

No End in Sight, Bladder Cancer Drug Shortage Takes a Toll
https://www.medscape.com/viewarticle/910407

Mar 13th, 2019 - A bacteria-based immunotherapy product that has been used in the treatment of bladder cancer for the past 40 years is now in short supply, and it appears that the situation will continue for the rest of 2019 at least. The shortage is now negativel...

Removing the C-Word From Low-Risk Diseases
https://www.medpagetoday.com/hematologyoncology/othercancers/74636

Aug 17th, 2018 - Recent advances in genomics and molecular biology have helped make a case to stop calling certain low-risk tumors "cancer," authors of a review of the issue concluded. Multiple studies have demonstrated that some tumors never grow and others grow ...

see more →